This plain language summary explains, in simple terms, the results of a study from 2022 discussing a biosimilar medicine called GP2017 (called SDZ-ADL in this summary, sold as Hyrimoz®). This medicine is used to treat people with inflammatory conditions. This study investigated a new, high-concentration formulation of GP2017 (SDZ-ADL-HCF) in order to show that the high concentration option acts the same way in the body as SDZ-ADL This Plain Language Summary of Publication article from Immunotherapy summarises the results from a 2022 study discussing a medicine called GP2017  (a biosimilar medicine) that is used in the treatment of inflammatory conditions. The study investigated a high-concentration formula of GP2017 (SDZ-ADL-HCF) to show that the high-concentration option acts in the same way in the body as the original concentration.

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar’ and was published in Expert Opinion on Biological Therapy. 

Visit Taylor & Francis Online using the link to read the original article.